Investing
Investing
I am a partner at DCVC. I find, fund, and grow deep tech startups that solve big problems in health, sustainability, and industrial transformation. I look for real innovations that can become the platforms of huge businesses, yielding years of breakthrough products or services.
Firms and Investments
-
![Dcvc logo whitespace 2]()
DCVC backs entrepreneurs solving trillion-dollar problems to multiply the benefits of capitalism for everyone while reducing its costs. For over twenty years, DCVC and its principals have backed brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry, especially those that haven’t seen material technological progress in decades. The firm has created tens of billions of dollars of value while also making the world a markedly better place.
-
![Totus logo new]()
Totus Medicines is a chemical biology company that has created a novel drug discovery platform that integrates structure-based design, combinatorial chemistry, and automated biophysics for the rapid identification of first-in-class oncology therapeutics.
-
![Menten logo]()
Menten AI combines synthetic biology, machine learning, and quantum computing to create new proteins not found in nature for applications in therapeutics and chemistry. The company’s hybrid quantum and machine learning approach allows them to overcome the scalability challenges that limit classical approaches.
-
![Zwitter Co Logo Primary Color]()
ZwitterCo’s membranes enable more sustainable and profitable wastewater reuse, protein production, and nutrient recovery.
-
![Image001]()
Kanvas uses microscopy to identify, quantify, and spatially position microbial organisms in their biological context. The approach allows biogeographical mapping of microorganisms with single-cell resolution, and has applications in environmental microbiology, microbiome research, and clinical diagnostics.
-
![Equilibrio logo AW POS]()
Equilibrio, still mostly in stealth, is pioneering a breakthrough $1 device for continuous monitoring of a wide variety of diseases.
-
![Aclaritylogo PNG 0 25 MP]()
Aclarity destroys wastewater contaminants, including highly toxic fluorinated chemicals, called Per- and Poly-Fluoroalkyl Substances (PFAS), that never break down in the environment and build up in our bodies, causing cancer, birth defects, and immune system disorders.
-
![Chemify rgb]()
Chemify is making code into molecules and molecules into code for better, faster, more useful drug discovery, chemical synthesis, and materials discovery.
-
![Relation]()
Relation Therapeutics is the pioneer of drug discovery using active-graph machine learning (ML) combined with single-cell analysis and deep clinical insights. Relation’s platform sits in an integrated wet-lab, dry-lab, translational science loop, located in London.
Jason was a critical partner in building Totus from the seed of an idea to a full-scale company with multiple therapeutic programs. We could not have done it without his support, feedback, and guidance.
— Neil Dhawan, CEO and Founder, Totus Medicines
How I Invest
I invest early: incubating a new concept when it’s a paper in Nature or Science, or leading the Seed or Series A rounds. I like to work with creative, disciplined founders from diverse backgrounds. If you’re a scientist-entrepreneur with a new idea, never think you don’t match the pattern of a typical founder: pitch me. If we work together, I’ll never mistake my role for an operator — it’s your job to run the company — but I’ll provide whatever your venture needs. My ethics are those of my firm, DCVC, which backs companies using deep tech to build a more abundant, resilient, and equitable future. I won’t invest in startups whose success would tend to erode human values like privacy, autonomy, or truth. Someone else can fund those companies.
Know how to solve a big problem? Pitch me here.
